Company / Financials
Ultragenyx Pharmaceutical Inc. Financials
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$673.0M
FY2025 · +20.2% YoY
Net Income
-$575.0M
FY2025 · -1.1% YoY
Profit Margin
-85.4%
FY2025 · net income / revenue
ROE
-
FY2025 · return on equity
Total Assets
$1.5B
FY2025
Total Debt
-
FY2025
Equity
-$80.0M
FY2025
ROA
-37.5%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$673.0M+20.2% YoYNet Income HistoryProfit after all expenses and taxes-$575.0M-1.1% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$1.1MOperating Income HistoryProfit from core business operations before interest and taxes-$535.0M+0.2% YoYSG&A Expense HistorySelling, general, and administrative expenses$349.0M+8.7% YoYR&D Expense HistoryResearch and development spending$750.0M+7.4% YoYIncome Tax HistoryTotal income tax expense$4.0M+100.0% YoYEPS (Basic) HistoryBasic earnings per share-$8.25+18.5% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$8.25+18.5% YoYShares Outstanding HistoryWeighted average diluted shares outstanding92.5M+12.4% YoY